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Abstract
Objective. We have investigated whether there is evidence that patients with soft tissue sarcomas do better if treated in a
specialist centre compared with district general hospitals.
Patients. All patients diagnosed with soft tissue sarcomas who were residents of WMRHA between 1994 and 1996, with
minimum follow up of 5 years, excluding head and neck or retroperitoneal tumors.
Methods. We reviewed data from the Royal Orthopaedic Hospital Oncology Service (ROHOS) database and the Cancer
Intelligence Unit (CIU) Database, with medial record review where necessary. Main outcome measures were local
recurrence and overall survival.
Results. A total of 260 patients were diagnosed as having STS over the 3-year period (incidence¼1.62per 100000 per
year):37% of patients had the majority of treatment at the specialist centre under the care of three surgeons, whilst the other
63% were treated at a total of 38 different hospitals. The rate of local recurrence was 39% at the district general hospitals
compared with 19% at the specialist centre despite the fact that tumours treated at the district hospitals were smaller and of
lower grade. The most significant factors affecting survival were grade (high versus low) and depth of the tumour. Patients
treated at the specialist centre had a small survival advantage after multivariate testing.
Conclusion. Soft tissue sarcomas are rare. Centralization of treatment improves local control in all patients and survival in
some. Appropriate mechanisms for ensuring that patients with soft tissue sarcomas are seen and treated at specialist centres
should be developed.
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Introduction
‘Cancer should be treated by cancer specialists’ is
often stated, but there is little proof that outcomes
are different. Soft Tissue Sarcomas (STS) represent
less than one percent of all malignancies and due
to such rarity, appropriate diagnosis, staging and
treatment is difficult and widely varied outside of
a specialist centre, due to lack of experience and
familiarity.
1,2 This is largely due to the lack of
realization that a lump may be malignant despite
published guidelines highlighting the features of
potential malignancy.
3
It is recommended that any lump that is either
bigger than 5cm, deep to the fascia, increasing in
size or painful should be considered to potentially
be a sarcoma and the patient should be referred to
an appropriate specialist centre before biopsy or sur-
gery.
4–6 This enables co-ordinated, specialist care by
a multidisciplinary team comprising of orthopaedic
oncology surgeons, pathologists and radiotherapists,
achieving wide margins at first attempt, thus reduc-
ing risk of local recurrence and further surgery.
7,8
Proving that centralization of care produces better
results is not, however, easy although there is some
information available for more common cancers,
such as breast, colorectal and oral cancer.
9–11 We
have investigated whether there is any difference in
outcome for patients with STS treated at a specialist
centre or a non-specialist District General Hospital
(DGH).
Patients and methods
We analysed the outcomes for all patients diagnosed
with soft tissue sarcomas in one health region of the
UK over a 3-year period, with minimum follow up of
5 years. The region has a population base of 5306497
(2620859 men and 2685638 women–1995 figures)
and has 38 District General Hospitals. Only one
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managing sarcomas during this time period and this
was designated the ‘specialist centre’ (SC).
Potentially eligible patients were initially identified
from the Cancer Intelligence Unit database. We
included any patient with a newly diagnosed STS
during the period of 1/1/1994 to 31/12/1996. Patients
with head and neck, GIST or retroperitoneal sarco-
mas were excluded. The CIU database contained
information on diagnosis, treatment and outcomes
for all patients with cancer in the Region and is
particularly reliable for death certification. Patients
who had their definitive treatment at the SC were
identified from the SC prospective patient database
and information from the two sources was used in
subsequent evaluations. In cases where there was
incomplete information reference was made to the
original patient records from the appropriate hospital.
Patients who were referred to the SC at a later stage
of their treatment (e.g., when they developed local
recurrence) were still included in the DGH group
as that was where they had their initial treatment,
but patients who were referred to the SC after biopsy
or excision biopsy were judged to have had their
definitive treatment at the Specialist Centre.
Ethical Committee Approval was obtained
from the Regional Multi-centre Research Ethical
Committee (MREC) for use of both databases,
and a letter sent to the Caldicott Guardian of each
NHS Trust explaining that data would be used to
analyse specialist versus non-specialist treatment
only, not to criticize individual surgeons or Trust
performance.
Statistical methods
Demographic details including the distribution of
age, size, grade and depth of STS are described along
with treatment variables. Difference between groups
were assessed using the Chi-squared test or t-test.
Overall survival was calculated using Kaplan–Meier
survival curves and the impact of prognostic factors
was assessed using the log-rank.
12,13 Multivariate
analysis was performed using Cox’s proportional
hazard method with variables being chosen using a
forward conditional stepwise approach. Relative risks
have been calculated using a proportional hazards
model with only the noted covariate in the model.
Significance was set at P<0.05 for two-sided tests.
Survival time was calculated from the time of
diagnosis when investigating the significance of
tumour and patient characteristics. The end point
was taken as time of death or the last documented
time the patient was known to be alive. Patients
who died of unrelated causes were censored at the
time of their death. Analyses were performed using
Statview.
14 When factor analysis was undertaken the
numbers involved have been highlighted.
Patients
A total of 116 patients were identified on the SC
database as being treated for soft tissue sarcoma
(excluding retroperitoneal and Kaposi’s Sarcomas)
between 1994 and 1996 inclusive and living in the
Region. Of these, 15 were identified to have received
treatment before 1994 and were thus excluded from
the study. Four were identified as having been
referred from a DGH for local recurrence within
the time period, and were found to be already
included on the DGH list. Patients referred for
re-excision, following inadvertent or incomplete
excision, were included on the SC list. One patient
was lost to follow-up. This resulted in the SC list
being 96 patients (117 (15þ4þ1þ1)¼96).
A total of 213 patients were identified by the CIU
as having been treated at a non-specialist centre and
residing in the region (excluding Kaposi’s sarcomas).
Of these, 42 were sarcomas of retroperitoneal origin
and were thus excluded. Five patients were identified
as being incorrectly classified as having STS, and two
had been treated before 1994. This resulted in DGH
list being 164 (213 (42þ5þ2)¼164).
The overall total sample size was thus 260 patients
over a 3-year period, resulting in an age-standardised
incidence ratio of 1.62per 100000 per year.
Results
Demographics
The distribution of patient and tumour character-
istics, split by centre of treatment is shown in Table 1.
The median age of the patients was 61 years with
a broad range (Fig. 1). 29 patients (11%) had
metastases at diagnosis, with the proportion at both
DGH and SC being the same. The prognosis for
these patients was awful (median survival 4 months)
and as a result these patients had been excluded from
all subsequent analyses of both treatment and
outcome.
Table 1 shows that patients treated at the specialist
centre tended to be younger and they had larger
tumours with a greater proportion of both deep and
high grade tumours. The most common diagnosis
was leiomyosarcoma (27%) followed by liposarcoma
(20%) and the most common site was in the thigh.
There was a significantly greater proportion of
patients with UICC (Union Internationale Contre
le Cancer) stage 3 tumours (high grade, deep, >5cm)
treated at the specialist centre than at the DGHs
(P¼0.0003).
15
Treatment
All patients without metastases at diagnosis under-
went excision of their STS with curative intention.
Amputation was the primary procedure in 8% of
2 A. A. Bhangu et al.cases with the other 92% having limb salvage
surgery. In cases where the margins of excision
were documented, adequate excision margins (a
wide or radical margin) were achieved in 37% of
cases (35% of DGH cases and 39% of SC cases).
Outcomes
Local control
Local recurrence arose in 73 patients (31%). It was
related to centre of treatment but not to the size
of the tumour, depth or grade. (Fig. 2, Table 2).
Patients with an adequate excision had a LR rate of
26% compared to a 40% risk in patients with an
inadequate excision. This was not however a signifi-
cant difference (P¼0.10). When local recurrence was
stratified by centre of treatment there was a highly
significant difference between the centres for all the
above parameters apart from small and low grade
tumours (Table 2).
Overall survival
The overall survival rate of the non metastatic
patients was 58% at 5 years and did not appear to
be significantly different between the two centres
(Fig. 3). Twenty patients died of unrelated causes
since the time of diagnosis. Apart from being
predominantly older than 60 there was no other
particular predominance of clinical features in this
Fig. 1. Age distribution of the 260 patients.
Fig. 2. Kaplan–Meier graph showing local control rates split
by centre of treatment (P¼0.0064).
Fig. 3. Kaplan–Meier curve of overall survival comparing the
two different treatment centres.
Table 1. Patient and treatment factors, split by centre
Factor Total DGH
(n¼164)
SC
(n¼96)
P value
Mean (median) age 57 (61) 58 (62) 54 (61) NS
Sex ratio (M/F) 149/111 91/73 58/38 NS
Mean size (cm)(median) 8.5 (7.0) 7.5 (4.8) 10.3 (9.0) 0.003
Proportion>5cm 57% 46% 73% 0.0001
Proportion of deep tumors 65% 60% 72% NS
Proportion of high grade tumours 71% 69% 79% 0.05
Metastases at presentation 11% 12% 11% NS
Large, high grade, deep tumours (UICC Stage 3) 31% 21% 45% 0.0003
Table 2. Outcome measures: local recurrence rates
Factor Total
(%)
DGH
(%)
SC
(%)
P value
All patients 32 39 19 0.0011
Subcutaneous 31 40 15 0.023
Deep 32 41 21 0.016
Large (>5cm) 30 45 21 0.0009
Small (<5cm) 33 37 16 0.15
High grade 33 41 20 0.0045
Low grade 29 35 12 0.06
Adequate margins 26 39 12 0.025
Inadequate margins 40 45 33 0.21
UICC stage 3 28 46 17 0.01
Others 31 38 18 0.018
Should soft tissue sarcomas be treated at a specialist centre? 3group. Factors related to survival are shown in
Table 3 using both univariate and multivariate
analysis. This confirms the expected prognostic
factors for disease related survival on univariate test-
ing; i.e., size at presentation, depth, age and grade.
Because of the significantly higher proportion of
patients with large, deep and high grade tumours
treated at the SC we have included centre of
treatment in the multivariate analysis, even though
it was not found to be significant on univariate
testing. This shows that whilst grade of tumour
remains the most significant factor affecting survival,
along with size and depth, the centre of treatment
just remains significant in the multivariate model.
Age loses its significance probably because of the
increasing number of non-tumour-related deaths
in this group. When analyzed by UICC state, how-
ever, the only significant difference between the two
centres is for stage 3 tumours, all other stages
showing no significant difference in overall survival
(Fig. 3).
Discussion
The aim of our study was to carry out a survival
analysis on patients treated at a specialist centre
compared to non-specialist centres (38 District
General Hospitals) in one Health Region in the UK.
We found similar proportions of patients with
large, high grade and deep tumours to those
identified in other population based studies.
4 We
did, however, find that the tumours of patients
treated at the specialist centre tended to be larger,
with a greater proportion being both high grade and
deep to the fascia. This is of importance as these
three factors are well established prognostic factors
for overall survival in STS.
16 The only factor carrying
a worse prognosis which was over represented in the
DGH population was older age (Fig. 4).
It is not surprising that patients with large and
deep tumours were seen at the specialist centre —
these are the lumps which should provoke most
suspicion of malignancy and this does indicate that
even in the time period under review (1994–1996)
there was a tendency for these ‘worrying’ lumps to be
referred to the specialist centre. Conversely, small
(<5cm), subcutaneous lumps are least likely to the
malignant and of the 52 patients with tumours in
this category, 38 (73%) were treated at the DGH
compared with 14 (27%) treated at the SC. Inter-
estingly, even in this group who should have a good
outlook both for local control and survival, there
were 13 LRs in the DGH group (34%) compared
with one (7%) in the SC group (P¼0.05). There
was no difference in overall survival in this good
prognosis group (UICC stages la and 2b).
The fact that the SC saw any of these small,
subcutaneous tumours may appear surprising but
many were referred for definitive treatment after
having had what is known as the ‘whoops’ procedure.
This is when a lump is excised, usually with little
forethought and without a biopsy and the surgeon is
then surprised when the pathologist reports it as a
sarcoma (hence the term ‘whoops’). The manage-
ment of these patients remains unresolved although
most authors now agree that wide re-excision to
obtain clear margins is necessary as residual tumour
will be found in anything between 30 and 60% of
cases.
17–19 Any patient who was thus referred was
considered to have had their definitive treatment at
the SC.
We have not in this study looked at all at the
quality of care given at the different centres. The SC
has defined guidelines for the management of
patients with STS and all cases were discussed at a
multidisciplinary team meeting. All patients will have
followed this protocol which includes preoperative
staging for both local and distant disease prior to
excision or re-excision of the tumour. Patients with
large, high grade or deep sarcomas were routinely
Fig. 4. Kaplan–Meier survival curve for patients with large
(>5cm), deep and high grade tumors only. The difference is
significant (P¼0.0032).
Table 3. Overall survival: univariate and multivariate analysis
Factor Univariate Multivariate
Hazard ratio Confidence limits P value Hazard ratio Confidence limits P value
DGH 0.96 0.63–1.47 0.84 1.7 1.01–2.8 0.048
Age>60 1.90 1.24–2.90 0.0029 NS
High grade 3.60 1.92–6.81 <0.0001 6.24 2.64–14.63 <0.0001
Deep 3.94 2.17–7.16 <0.0001 3.10 1.64–5.84 0.0005
Small (<5cm) 0.42 0.26–0.70 0.0008 0.52 0.30–0.92 0.024
4 A. A. Bhangu et al.treated with adjuvant radiotherapy according to this
protocol. Chemotherapy was not routinely used for
this patient population but was used for palliative
management. It is likely that patients treated at a
DGH will not have been treated within this protocol
and whilst some will have been referred to an
oncologist for further management we feel that it is
unlikely there would have been much difference
between this patient population and that identified
by Clasby et al. and Jane et al. in their respective
papers identifying very poor compliance with any
accepted guidelines for care of sarcomas outside a
specialist setting.
1,2
Furthermore, we did not review the histology of
the patients treated outside the specialist centre.
Whilst this would have been a counsel of perfection,
the ethical ramifications of potentially reclassifying
patients with alleged STS into another diagnostic
category is still not fully resolved. Previous experi-
ence of reviewing the pathological diagnoses of STS
has shown significant errors of overdiagnosis in up to
24%.
20,21 If some patients treated for STS at a DGH
did not actually have STS then this would mean that
those patients would have neither had local recur-
rence nor disease relapse and they could only have
artificially improved these rates for DGH patients.
The ability to achieve adequate margins of exci-
sion was similar in both groups even though the
DGHs had a larger proportion of smaller, superficial
tumours. This was, however, not then reflected in
similar rates of local recurrence. A positive margin at
a DGH confers a 45% risk of LR compared with a
33% risk at the SC. It is possible that this is because
of the use of other adjuvants at the SC such as
radiotherapy but we did not investigate this as part of
the study. What was even more concerning, however,
was the observation that even with allegedly clear
margins at the DGH the local recurrence rate was
39% compared to 12% at the SC. This could be
because of a false sense of security being produced
by the pathologist’s report of clear margins and
consequent lack of further adjuvant treatment.
Again, review of the pathology reports for accuracy,
both in terms of diagnosis and assessment of margin
was outside the breadth of this study.
We have shown that local control is dramatically
better at the SC compared to patients treated at the
DGHs and this is true for virtually all categories.
Whilst we are not happy with a local relapse rate of
19% at the SC this is equivalent to those in many
series. We feel however that a 40% local failure rate
at DGHs is unacceptable and will have undoubtedly
resulted in significant further morbidity, hospital
admissions and treatment although we have made no
attempt to quantify this.
The overall survival of patients in this study
population was 58% at 5 years which is towards
the lower limit of those published results.
1,4,16 We
have shown that the same prognostic factors are
significant in this population as in most other series
of STS patients. Centre of treatment does not reach
significance on univariate analysis but this can be
explained by the disproportionate number of small,
low grade and subcutaneous tumours treated at the
DGHs patients who should have a better prognosis.
Centre of treatment does, however, become signifi-
cant on multivariate analysis when these factors are
taken into account. The reason for the difference is
not clear from this study. One might think that the
increased local recurrence rate could be responsible
for this but the role of local recurrence in overall
survival remains controversial with no clearcut
evidence that local relapse per se is an independent
poor prognostic factor.
22,23
We have investigated the significance of LR in this
cohort of patients and have found that the presence
of local relapse by itself would appear to be sig-
nificant in predicting overall survival on univariate
analysis (P<0.0001). If, however, one uses LR as a
time-dependent variable (i.e., only including patients
who developed local recurrence who did not already
have metastases), it is no longer significant.
We conclude that this study has shown nearly
identical findings to that of Gustafson in that STS
treated at DGHs have a much higher rate of local
relapse than those treated at the centre.
7 We have
also identified for the first time that there may also
be a small survival advantage to being treated at a
specialist centre. We would recommend that clear
network paths should be developed so that all
suspicious lumps should be screened to rule out
the possibility of malignancy and that any patient
with a soft tissue sarcoma should be treated within
a defined protocol to minimize the risk of local
recurrence and maximize the chances of survival. At
this point in time, this would mean referral to a
specialist treatment centre for appropriate review of
pathology and advice on the role of surgery,
chemotherapy and radiotherapy.
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